Lundbeck could introduce gene chip-technology for depressive patients within ten years
Within the next ten years Danish company Lundbeck expects to be able to indicate to depressive patients exactly which type of medicine will work for them, simply by having them take a blood test. However, the pharmaceutical company has already lost the first round of the gene chip-race.
af LEONORA BECK
There is a wide array of anti-depressants out there, but most of the time the drugs only work on a small segment of the depressive patients. Lundbeck is well on the way to discover a method to determine whether or not a patient suffers from depression, and if so, exactly which kind of depression.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
